

Linjie Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4010409/publications.pdf>

Version: 2024-02-01

33
papers

1,448
citations

471509

17
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

2727
citing authors

#	ARTICLE	IF	CITATIONS
1	Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. <i>Science Translational Medicine</i> , 2022, 14, eabf3917.	12.4	13
2	Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence. <i>Oncogene</i> , 2022, 41, 895-906.	5.9	22
3	A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells. <i>Molecular Cell</i> , 2022, 82, 1123-1139.e8.	9.7	18
4	Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges. <i>Trends in Cancer</i> , 2021, 7, 541-556.	7.4	11
5	Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs. <i>Science Advances</i> , 2021, 7, .	10.3	25
6	Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics. <i>Oncogene</i> , 2021, 40, 6059-6070.	5.9	13
7	Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	9
8	Immunoregulatory Functions of Nuclear Receptors: Mechanisms and Therapeutic Implications. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 93-106.	7.1	5
9	Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy. <i>IScience</i> , 2020, 23, 101458.	4.1	15
10	Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. <i>Cell Research</i> , 2020, 30, 833-853.	12.0	149
11	Nuclear Receptors in Cancer Inflammation and Immunity. <i>Trends in Immunology</i> , 2020, 41, 172-185.	6.8	19
12	Nuclear receptors: recent drug discovery for cancer therapies. <i>Endocrine Reviews</i> , 2019, 40, 1207-1249.	20.1	65
13	Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	112
14	Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling. <i>Cancer Discovery</i> , 2019, 9, 1248-1267.	9.4	120
15	Functional Peptides and Small Molecules in Medicinal Chemistry-Part I. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2-3.	2.1	1
16	RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. <i>Npj Precision Oncology</i> , 2019, 3, 13.	5.4	23
17	Functional Peptides and Small Molecules in Medicinal Chemistry-Part II. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 186-186.	2.1	0
18	Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. <i>Oncogene</i> , 2019, 38, 2305-2319.	5.9	41

#	ARTICLE	IF	CITATIONS
19	Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3673-E3681.	7.1	56
20	The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts. <i>Genome Biology</i> , 2018, 19, 35.	8.8	68
21	Epigenetics in ovarian cancer: premise, properties, and perspectives. <i>Molecular Cancer</i> , 2018, 17, 109.	19.2	87
22	A mass spectrometric insight into the origins of benign gynecological disorders. <i>Mass Spectrometry Reviews</i> , 2017, 36, 450-470.	5.4	16
23	Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer. <i>Cancer Research</i> , 2017, 77, 1369-1382.	0.9	184
24	A simple method based on Sanger sequencing and MS Word wildcard searching to identify Cas9-induced frameshift mutations. <i>Laboratory Investigation</i> , 2017, 97, 1500-1507.	3.7	5
25	Wolfâ€“Hirschhorn Syndrome Candidate 1 (whsc1) Functions as a Tumor Suppressor by Governing Cell Differentiation. <i>Neoplasia</i> , 2017, 19, 606-616.	5.3	20
26	LncRNAs: the bridge linking RNA and colorectal cancer. <i>Oncotarget</i> , 2017, 8, 12517-12532.	1.8	33
27	eIF3i activity is critical for endothelial cells in tumor induced angiogenesis through regulating VEGFR and ERK translation. <i>Oncotarget</i> , 2017, 8, 19968-19979.	1.8	9
28	Tumor microenvironment: The culprit for ovarian cancer metastasis?. <i>Cancer Letters</i> , 2016, 377, 174-182.	7.2	149
29	Menopause-induced uterine epithelium atrophy results from arachidonic acid/prostaglandin E2 axis inhibition-mediated autophagic cell death. <i>Scientific Reports</i> , 2016, 6, 31408.	3.3	26
30	Complementing the tumor-specific immunity in tumor radiotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 289-289.	1.7	0
31	Increased expression of fibroblast growth factor receptor 1 in endometriosis and its correlation with endometriosis-related dysmenorrhea and recurrence. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 184, 117-124.	1.1	13
32	MicroRNAs in colorectal cancer: Small molecules with big functions. <i>Cancer Letters</i> , 2015, 360, 89-105.	7.2	80
33	The expression and functionality of stromal caveolin 1 in human adenomyosis. <i>Human Reproduction</i> , 2013, 28, 1324-1338.	0.9	28